<?xml version="1.0" encoding="utf-8"?>


<DOCUMENT xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dart3.xsd">

<DOCUMENT-NAME ACODE="10800">증권발행실적보고서</DOCUMENT-NAME>
<FORMULA-VERSION ADATE="20220117">2.6</FORMULA-VERSION>
<COMPANY-NAME AREGCIK="00545929">주식회사 제넥신</COMPANY-NAME>


<BODY>

<COVER>
<COVER-TITLE ATOC="Y" AASSOCNOTE="COVER">증권발행실적보고서</COVER-TITLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="152"></COL>
<COL WIDTH="430"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" COLSPAN="2" WIDTH="600" HEIGHT="53"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30">금융감독원장 귀하</TD>
<TD CLASS="NORMAL" ALIGN="RIGHT" WIDTH="439" HEIGHT="30">2023년      01월     10일</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="53"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="53"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="53">회       사       명 :</TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="53">(주)제넥신</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="53">대   표     이   사 :</TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="53">Neil Warma, 우정원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30">본  점  소  재  지 :</TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30">서울특별시 강서구 마곡중앙로 172 바이오이노베이션파크</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30">(전  화) 02-6098-2600</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30">(홈페이지) http://www.genexine.com</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30">작  성  책  임  자 :</TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30">(직  책) C F O                  (성  명) 홍 성 준</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="30"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="30">(전  화) 02-6098-2600</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD CLASS="NORMAL" WIDTH="161" HEIGHT="53"></TD>
<TD CLASS="NORMAL" WIDTH="439" HEIGHT="53"></TD>
</TR>
</TBODY>
</TABLE>
</COVER>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">

<LIBRARY>
<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-1-0">Ⅰ. 발행개요</TITLE>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">1. 기업개요</TITLE>

<TABLE-GROUP ACLASS="CRP_OTLN" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="191"></COL>
<COL WIDTH="191"></COL>
<COL WIDTH="191"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">상장구분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">기업규모</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">업종구분</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TU WIDTH="200" HEIGHT="30" AUNIT="CRP_RGS_CLS" VALIGN="MIDDLE" ALIGN="CENTER" AUNITVALUE="2">코스닥</TU>
<TU WIDTH="200" HEIGHT="30" AUNIT="CRP_SCL" VALIGN="MIDDLE" ALIGN="CENTER" AUNITVALUE="2">중소기업</TU>
<TU WIDTH="200" HEIGHT="30" AUNIT="CRP_CODE" VALIGN="MIDDLE" ALIGN="CENTER" AUNITVALUE="70">연구개발업</TU>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">2. 발행 개요</TITLE>

<TABLE-GROUP ACLASS="PBL_OTLN" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="291"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="191"></COL>
<COL WIDTH="191"></COL>
<COL WIDTH="191"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">구분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">발행총액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="200" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비고</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TU WIDTH="200" HEIGHT="30" AUNIT="DST_SMR" VALIGN="MIDDLE" ALIGN="CENTER" AUNITVALUE="3">기타</TU>
<TE WIDTH="200" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" ACODE="INC_SL_PO_SUM">85,217,399,400</TE>
<TE WIDTH="200" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" ACODE="NOTE">주주배정후 실권주 일반공모</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-2-0">Ⅱ. 청약 및 배정에 관한 사항</TITLE>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">1. 청약 및 납입일정</TITLE>

<TABLE-GROUP ACLASS="SB_DT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">구분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">청약개시일</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">청약종료일</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">납입기일</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="53" ACODE="SB_CO">구주주청약(초과청약 포함)</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="53" AUNIT="SB_STR_DT" AUNITVALUE="20230102">2023년 01월 02일</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="53" AUNIT="SB_END_DT" AUNITVALUE="20230103">2023년 01월 03일</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="53" AUNIT="PYM_DT" AUNITVALUE="20230110">2023년 01월 10일</TU>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="53" ACODE="SB_CO">일반공모</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="53" AUNIT="SB_STR_DT" AUNITVALUE="20230105">2023년 01월 05일</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="53" AUNIT="SB_END_DT" AUNITVALUE="20230106">2023년 01월 06일</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="53" AUNIT="PYM_DT" AUNITVALUE="20230110">2023년 01월 10일</TU>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">2. 인수기관별 인수금액</TITLE>

<TABLE-GROUP ACLASS="ACC_AMT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="291"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="139"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="107"></COL>
<COL WIDTH="102"></COL>
<COL WIDTH="97"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="148" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">인수기관</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">인수수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="116" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">인수금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비 율(%)</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="106" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비  고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="148" HEIGHT="30" ACODE="ACC_ORG">한국투자증권(주)</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="119" HEIGHT="30" ACODE="ACC_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="116" HEIGHT="30" ACODE="ACC_AMT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACODE="ACC_RT">-</TE>
<TE VALIGN="MIDDLE" WIDTH="106" HEIGHT="30" ACODE="NOTE" ALIGN="RIGHT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="148" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="119" HEIGHT="30" ACODE="TOT_ACC_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="116" HEIGHT="30" ACODE="TOT_ACC_AMT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACODE="TOT_ACC_RT">-</TE>
<TE VALIGN="MIDDLE" WIDTH="106" HEIGHT="30" ACODE="TOT_NOTE" ALIGN="RIGHT">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">3. 청약 및 배정현황</TITLE>

<TABLE-GROUP ACLASS="DST_CD" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="1071" BORDER="0">

<COLGROUP>
<COL WIDTH="420"></COL>
<COL WIDTH="633"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="429" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" WIDTH="642" HEIGHT="30" AUNIT="WONSTOCKPERCENT" AUNITVALUE="1">(단위 : 원, 주, %)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="1071" BORDER="1">

<COLGROUP>
<COL WIDTH="171"></COL>
<COL WIDTH="98"></COL>
<COL WIDTH="48"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="98"></COL>
<COL WIDTH="127"></COL>
<COL WIDTH="39"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="93"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="46"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="180" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">구  분</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="164" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">최초 배정</TH>
<TH COLSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="369" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">청약 현황</TH>
<TH COLSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="358" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">최종 배정 현황</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="107" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="57" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비율</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">건수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="107" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="136" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비율</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="80" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">건수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="121" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="55" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비율</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="180" HEIGHT="30" ACODE="DST_CD">구주주(신주인수권증서)</TE>
<TE ALIGN="RIGHT" WIDTH="107" HEIGHT="30" ACODE="FST_DV_CNT">  5,797,102</TE>
<TE ALIGN="RIGHT" WIDTH="57" HEIGHT="30" ACODE="FST_DV_RT">  100 </TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="SB_CNT">  33,997</TE>
<TE ALIGN="RIGHT" WIDTH="107" HEIGHT="30" ACODE="SB_ST_CNT">4,972,068</TE>
<TE ALIGN="RIGHT" WIDTH="136" HEIGHT="30" ACODE="SB_AMT">73,089,399,600</TE>
<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="30" ACODE="SB_RT">7.56</TE>
<TE ALIGN="RIGHT" WIDTH="80" HEIGHT="30" ACODE="DV_CNT">  33,997</TE>
<TE ALIGN="RIGHT" WIDTH="102" HEIGHT="30" ACODE="DV_ST_CNT">4,972,068</TE>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="DV_AMT">73,089,399,600</TE>
<TE ALIGN="RIGHT" WIDTH="55" HEIGHT="30" ACODE="DV_RT">85.77</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="180" HEIGHT="30" ACODE="DST_CD">구주주(초과청약)</TE>
<TE ALIGN="RIGHT" WIDTH="107" HEIGHT="30" ACODE="FST_DV_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="57" HEIGHT="30" ACODE="FST_DV_RT">-</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="SB_CNT">  23,381</TE>
<TE ALIGN="RIGHT" WIDTH="107" HEIGHT="30" ACODE="SB_ST_CNT">609,205</TE>
<TE ALIGN="RIGHT" WIDTH="136" HEIGHT="30" ACODE="SB_AMT">8,955,313,500</TE>
<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="30" ACODE="SB_RT">0.93</TE>
<TE ALIGN="RIGHT" WIDTH="80" HEIGHT="30" ACODE="DV_CNT">  23,381</TE>
<TE ALIGN="RIGHT" WIDTH="102" HEIGHT="30" ACODE="DV_ST_CNT">609,205</TE>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="DV_AMT">8,955,313,500</TE>
<TE ALIGN="RIGHT" WIDTH="55" HEIGHT="30" ACODE="DV_RT">10.51</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="180" HEIGHT="30" ACODE="DST_CD">실권주 일반공모</TE>
<TE ALIGN="RIGHT" WIDTH="107" HEIGHT="30" ACODE="FST_DV_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="57" HEIGHT="30" ACODE="FST_DV_RT">-</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="SB_CNT">2,500</TE>
<TE ALIGN="RIGHT" WIDTH="107" HEIGHT="30" ACODE="SB_ST_CNT">60,179,565</TE>
<TE ALIGN="RIGHT" WIDTH="136" HEIGHT="30" ACODE="SB_AMT">884,639,605,500</TE>
<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="30" ACODE="SB_RT">91.51</TE>
<TE ALIGN="RIGHT" WIDTH="80" HEIGHT="30" ACODE="DV_CNT">2,347</TE>
<TE ALIGN="RIGHT" WIDTH="102" HEIGHT="30" ACODE="DV_ST_CNT">215,829</TE>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="DV_AMT">3,172,686,300</TE>
<TE ALIGN="RIGHT" WIDTH="55" HEIGHT="30" ACODE="DV_RT">3.72</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" WIDTH="180" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" WIDTH="107" HEIGHT="30" ACODE="FST_DV_CNT_TOT">  5,797,102</TE>
<TD ALIGN="RIGHT" WIDTH="57" HEIGHT="30" AUPDATECONT="N">100</TD>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="SB_CNT_TOT">59,878</TE>
<TE ALIGN="RIGHT" WIDTH="107" HEIGHT="30" ACODE="SB_ST_CNT_TOT">65,760,838</TE>
<TE ALIGN="RIGHT" WIDTH="136" HEIGHT="30" ACODE="SB_AMT_TOT">966,684,318,600</TE>
<TD ALIGN="RIGHT" WIDTH="48" HEIGHT="30" AUPDATECONT="N">100</TD>
<TE ALIGN="RIGHT" WIDTH="80" HEIGHT="30" ACODE="DV_CNT_TOT">59,725</TE>
<TE ALIGN="RIGHT" WIDTH="102" HEIGHT="30" ACODE="DV_ST_CNT_TOT">5,797,102</TE>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="DV_AMT_TOT">85,217,399,400</TE>
<TD ALIGN="RIGHT" WIDTH="55" HEIGHT="30" AUPDATECONT="N">100</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">4. 일반투자자 배정방식별 배정현황</TITLE>

<TABLE-GROUP ACLASS="NOR_ASS" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">구분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">배정수량(주)</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중(%)</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">균등방식 유형</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUPDATECONT="N">균등방식</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="EQV_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="EQV_RT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="EQV_TYP">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUPDATECONT="N">비례방식</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="PRP_CNT">215,829</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="PRP_RT">100</TE>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUPDATECONT="N">-</TD>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="CNT_TOT">215,829</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACODE="RT_TOT">100</TE>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" AUPDATECONT="N">-</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">5. 기관투자자 의무보유확약기간별 배정현황</TITLE>

<TABLE-GROUP ACLASS="INS_ASS" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="804" BORDER="0">

<COLGROUP>
<COL WIDTH="393"></COL>
<COL WIDTH="393"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="402" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="402" HEIGHT="30" AUNIT="STOCKPERCENT" AUNITVALUE="1">(단위 : 주, %)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="804" BORDER="1">

<COLGROUP>
<COL WIDTH="79"></COL>
<COL WIDTH="43"></COL>
<COL WIDTH="43"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="42"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="88" HEIGHT="136" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">확약기간</TH>
<TH COLSPAN="8" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="410" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">국내 기관투자자</TH>
<TH COLSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="204" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">외국 기관투자자</TH>
<TH ROWSPAN="2" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="106" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">합계</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="104" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">운용사(집합)</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">투자매매ㆍ중개업자</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">연기금,운용사(고유)은행,보험</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">기타</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">거래실적유</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="102" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">거래실적무</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비중</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="88" HEIGHT="30" ACODE="ASS_PRD">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="IN_MNG_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="IN_MNG_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_BRK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_BRK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_BNK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_BNK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_ETC_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="IN_ETC_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="EX_TRY_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="EX_TRY_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="EX_TRN_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="EX_TRN_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TOT_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TOT_RT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="88" HEIGHT="30" AUPDATECONT="N">미확약</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="NIN_MNG_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="NIN_MNG_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_BRK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_BRK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_BNK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_BNK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_ETC_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NIN_ETC_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NEX_TRY_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NEX_TRY_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NEX_TRN_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NEX_TRN_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NTOT_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="NTOT_RT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="88" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="TIN_MNG_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="52" HEIGHT="30" ACODE="TIN_MNG_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_BRK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_BRK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_BNK_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_BNK_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_ETC_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TIN_ETC_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TEX_TRY_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TEX_TRY_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TEX_TRN_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TEX_TRN_RT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TTOT_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACODE="TTOT_RT">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-3-0">Ⅲ. 유상증자 전후의 주요주주 지분변동</TITLE>
<P></P>

<TABLE WIDTH="617" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="608"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="617" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(단위 : 주, %)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="618" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="59"></COL>
<COL WIDTH="79"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="91"></COL>
<COL WIDTH="91"></COL>
<COL WIDTH="91"></COL>
<COL WIDTH="90"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="68" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60">성명</TH>
<TH ROWSPAN="2" WIDTH="88" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60">관 계</TH>
<TH ROWSPAN="2" WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60">주식의종류</TH>
<TH COLSPAN="2" WIDTH="200" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">증자 전</TH>
<TH COLSPAN="2" WIDTH="199" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">증자 후</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="100" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">주식수</TH>
<TH WIDTH="100" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">지분율</TH>
<TH WIDTH="100" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">주식수</TH>
<TH WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">지분율</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="68" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">(주)한독</TD>
<TD WIDTH="88" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">최대주주</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="100" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,781,017</TD>
<TD WIDTH="100" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15.04</TD>
<TD WIDTH="100" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,652,719</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15.04</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="156" VALIGN="MIDDLE" ALIGN="CENTER" ROWSPAN="2" HEIGHT="60">소 계</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주</TD>
<TD WIDTH="100" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,781,017</TD>
<TD WIDTH="100" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15.04</TD>
<TD WIDTH="100" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,652,719</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15.04</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">우선주</TD>
<TD WIDTH="100" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="100" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="100" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>
<P>주1) 증자 전 발행주식총수 : 25,144,982주주2) 증자 후 발행주식총수 : 30,942,084주</P>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-4-0">Ⅳ. 증권교부일 등</TITLE>
<P>- 주권상장 및 유통 예정일 : 2023년 01월 26일(목)</P>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-5-0">Ⅴ. 공시 이행상황</TITLE>
<P></P>
<P>1. 공고의 일자 및 방법</P>

<TABLE BORDER="1" WIDTH="652" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="222"></COL>
<COL WIDTH="144"></COL>
<COL WIDTH="259"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">구 분</TH>
<TH WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">공고일자</TH>
<TH WIDTH="268" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">공고방법</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">신주발행공고 및배정기준일(주주확정일) 공고</TD>
<TD WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">2022년 09월 28일</TD>
<TD WIDTH="268" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">당사 인터넷 홈페이지(http://www.genexine.com)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">신주발행공고 및 배정기준일(주주확정일) 정정공고</TD>
<TD WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">2022년 10월 20일</TD>
<TD WIDTH="268" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">당사 인터넷 홈페이지(http://www.genexine.com)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">모집가액 확정의 공고</TD>
<TD WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">2022년 12월 28일</TD>
<TD WIDTH="268" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">당사 인터넷 홈페이지(http://www.genexine.com)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">실권주 일반공모 청약공고</TD>
<TD WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">2023년 01월 04일</TD>
<TD WIDTH="268" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">당사 인터넷 홈페이지(http://www.genexine.com)한국투자증권㈜ 홈페이지(http://www.truefriend.com)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="231" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">실권주 일반공모 배정공고</TD>
<TD WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">2023년 01월 10일</TD>
<TD WIDTH="268" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">한국투자증권㈜ 홈페이지(http://www.truefriend.com)</TD>
</TR>
</TBODY>
</TABLE>
<P>2. 증권신고서가. 전자문서 : 금융위(금감원) 전자공시시스템 →  http://dart.fss.or.kr나. 증권신고서 제출일 :</P>
<P>[증권신고서 제출 및 정정 연혁]</P>

<TABLE BORDER="1" WIDTH="800" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="128"></COL>
<COL WIDTH="286"></COL>
<COL WIDTH="359"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="137" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">제출일자</TH>
<TH WIDTH="295" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">문서명</TH>
<TH WIDTH="368" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 09월 27일</TD>
<TD WIDTH="295" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">증권신고서(지분증권)</TD>
<TD WIDTH="368" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">최초제출</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 10월 21일</TD>
<TD WIDTH="295" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[기재정정]증권신고서(지분증권)</TD>
<TD WIDTH="368" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">정정제출 요구 및 일정변경에 따른 정정(파란색)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 11월 08일</TD>
<TD WIDTH="295" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[발행조건확정]증권신고서(지분증권)</TD>
<TD WIDTH="368" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">기재정정(초록색)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">2022년 11월 15일</TD>
<TD WIDTH="295" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">[기재정정]증권신고서(지분증권)</TD>
<TD WIDTH="368" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">3분기 분기보고서 제출에 따른 기재정정(빨간색)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 12월 05일</TD>
<TD WIDTH="295" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[기재정정]증권신고서(지분증권)</TD>
<TD WIDTH="368" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">단순오기 기재정정(보라색)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 12월 08일</TD>
<TD WIDTH="295" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[기재정정]증권신고서(지분증권)</TD>
<TD WIDTH="368" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">일정 변경에 따른 기재정정(주황색)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="137" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 12월 28일</TD>
<TD WIDTH="295" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[발행조건확정]증권신고서(지분증권)</TD>
<TD WIDTH="368" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">기재정정(갈색)</TD>
</TR>
</TBODY>
</TABLE>
<P>3. 투자설명서가. 전자문서 : 금융위(금감원) 전자공시시스템 →  http://dart.fss.or.kr나. 서면문서 : (주)제넥신 → 서울시 강서구 마곡중앙로 172 바이오이노베이션파크                        한국투자증권(주) → 서울시 영등포구 의사당대로 88               </P>

<TABLE WIDTH="706" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="697"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="706" VALIGN="BOTTOM" HEIGHT="30">[투자설명서 제출 및 정정 연혁]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="705" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="143"></COL>
<COL WIDTH="180"></COL>
<COL WIDTH="355"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="152" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">제출일자</TH>
<TH WIDTH="189" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">문서명</TH>
<TH WIDTH="364" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 11월 07일</TD>
<TD WIDTH="189" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">투자설명서</TD>
<TD WIDTH="364" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">최초제출</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 11월 08일</TD>
<TD WIDTH="189" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[기재정정]투자설명서</TD>
<TD WIDTH="364" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">기재정정(초록색)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 11월 15일</TD>
<TD WIDTH="189" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[기재정정]투자설명서</TD>
<TD WIDTH="364" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">3분기 분기보고서 제출에 따른 기재정정(빨간색)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 12월 05일</TD>
<TD WIDTH="189" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[기재정정]투자설명서</TD>
<TD WIDTH="364" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">단순오기 기재정정(보라색)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 12월 08일</TD>
<TD WIDTH="189" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[기재정정]투자설명서</TD>
<TD WIDTH="364" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">일정 변경에 따른 기재정정(주황색)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2022년 12월 28일</TD>
<TD WIDTH="189" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">[기재정정]투자설명서</TD>
<TD WIDTH="364" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">최종 발행가액 확정(갈색)</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-6-0">Ⅵ. 조달된 자금의 사용내역</TITLE>
<P></P>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">1. 자금조달 내용</TITLE>

<TABLE-GROUP ACLASS="INC_SL" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="299"></COL>
<COL WIDTH="283"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="308" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="292" HEIGHT="30" AUNIT="WONSTOCK" AUNITVALUE="1">(단위 : 원, 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="39"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="68"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">구분</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">주식구분</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="121" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">신고서상발행예정총액</TH>
<TH COLSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="291" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">실제 조달금액</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="77" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">비고</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">발행가액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">수 량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="121" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">발행총액</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TD ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="60" AUPDATECONT="N">모집</TD>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="INC_RPT_MN">85,217,399,400</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="INC_STK_AMT">14,700</TE>
<TE ALIGN="RIGHT" WIDTH="92" HEIGHT="30" ACODE="INC_STK_CNT">5,797,102</TE>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="INC_STK_TOT">85,217,399,400</TE>
<TE WIDTH="77" HEIGHT="30" ACODE="INC_NOTE" VALIGN="MIDDLE" ALIGN="CENTER">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="INC_RPT_TOT">85,217,399,400</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="INC_AMT_TOT">14,700</TE>
<TE ALIGN="RIGHT" WIDTH="92" HEIGHT="30" ACODE="INC_CNT_TOT">5,797,102</TE>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="INC_TOT">85,217,399,400</TE>
<TE WIDTH="77" HEIGHT="30" ACODE="INC_NOTE_TOT" VALIGN="MIDDLE" ALIGN="CENTER">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TD ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="60" AUPDATECONT="N">매출</TD>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" ACODE="SL_STK_KND">-</TE>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="SL_RPT_MN">-</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="SL_STK_AMT">-</TE>
<TE ALIGN="RIGHT" WIDTH="92" HEIGHT="30" ACODE="SL_STK_CNT">-</TE>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="SL_STK_TOT">-</TE>
<TE WIDTH="77" HEIGHT="30" ACODE="SL_NOTE" VALIGN="MIDDLE" ALIGN="CENTER">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="SL_RPT_TOT">-</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="SL_AMT_TOT">-</TE>
<TE ALIGN="RIGHT" WIDTH="92" HEIGHT="30" ACODE="SL_CNT_TOT">-</TE>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="SL_TOT">-</TE>
<TE WIDTH="77" HEIGHT="30" ACODE="SL_NOTE_TOT" VALIGN="MIDDLE" ALIGN="CENTER">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" AUPDATECONT="N">총  계</TD>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="INC_SL_RPT_SUM">85,217,399,400</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="30" ACODE="INC_SL_AMT_SUM">14,700</TE>
<TE ALIGN="RIGHT" WIDTH="92" HEIGHT="30" ACODE="INC_SL_CNT_SUM">5,797,102</TE>
<TE ALIGN="RIGHT" WIDTH="121" HEIGHT="30" ACODE="INC_SL_SUM">85,217,399,400</TE>
<TE WIDTH="77" HEIGHT="30" ACODE="TOT_NOTE" VALIGN="MIDDLE" ALIGN="CENTER">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
</SECTION-3>

<SECTION-3 ACLASS="MANDATORY">
<TITLE ATOC="Y">2. 자금의 사용목적</TITLE>
<P>가. 자금의 사용목적당사가 금번 보통주 유상증자를 통해 조달 예정인 자금 85,217,399,400원은 운영자금(임상자금 및 기타 운영자금 등)으로 사용할 계획입니다.</P>

<TABLE-GROUP ACLASS="INC_PRPS" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="616" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="307"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="316" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="617" BORDER="1">

<COLGROUP>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="84"></COL>
<COL WIDTH="39"></COL>
<COL WIDTH="112"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">시설자금</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">영업양수자금</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="121" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">운영자금</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">채무상환자금</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">타법인증권취득자금</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">기타</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="121" HEIGHT="53" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">계</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TE WIDTH="78" HEIGHT="30" ACODE="FND_USE1" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
<TE WIDTH="78" HEIGHT="30" ACODE="FND_USE_SQ" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
<TE WIDTH="121" HEIGHT="30" ACODE="FND_USE2" VALIGN="MIDDLE" ALIGN="RIGHT">85,217,399,400</TE>
<TE WIDTH="78" HEIGHT="30" ACODE="FND_USE5" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
<TE WIDTH="93" HEIGHT="30" ACODE="FND_USE_AS" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
<TE WIDTH="48" HEIGHT="30" ACODE="FND_USE4" VALIGN="MIDDLE" ALIGN="RIGHT">-</TE>
<TE WIDTH="121" HEIGHT="30" ACODE="FND_USE_SUM" VALIGN="MIDDLE" ALIGN="RIGHT">85,217,399,400</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P></P>
<P>나. 자금의 세부 사용내역</P>
<P>당사는 금번 유상증자로 조달된 자금을 현재 개발 중인 파이프라인 중 GX-188E(자궁경부암 치료백신, HPV16/18 유래암치료 DNA 백신)의 다국가 임상3상 수행을 위한 R&D비용 및 GX-I7(항암 면역치료제)의 향후 상업화를 위한 임상개발 및 PPQ(공정성능적격성 평가)배치 생산/분석 등에 투자할 계획이며, 그 외에도 당사의 주요 파이프라인인 GX-E4, GX-H9 등의 연구개발비용으로 사용할 계획입니다. 만약 금번 유상증자의 공모 금액이 당초 계획한 금액에 미달할 경우, 당사는 아래에 표기한 자금사용계획 우선순위에 따라 집행 시기를 고려하여 세부적으로 조정할 예정이며, 부족분 및 발행제비용은 당사의 자체자금으로 충당할 계획입니다. 금번 유상증자를 통한 공모 자금의 세부 사용 내역은 아래와 같습니다.</P>
<P></P>

<TABLE ACLASS="NORMAL" WIDTH="566" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="557"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="566" HEIGHT="30">[자금사용 우선순위]</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="566" HEIGHT="30">(단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="571">

<COLGROUP>
<COL WIDTH="80"></COL>
<COL WIDTH="113"></COL>
<COL WIDTH="70"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="69"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH COLSPAN="3" WIDTH="290" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">구   분</TH>
<TH WIDTH="123" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">사용(예정)시기</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">금액</TH>
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">우선순위</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ROWSPAN="8" ALIGN="CENTER" WIDTH="89" HEIGHT="240">(R&D비용)</TD>
<TD VALIGN="MIDDLE" ROWSPAN="4" ALIGN="CENTER" WIDTH="122" HEIGHT="120">CMC(생산 및 품질)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="79" HEIGHT="30">GX-188E</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="123" HEIGHT="30">2023년~2025년</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="80" HEIGHT="30">5,588</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="78" HEIGHT="30">4순위</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="79" HEIGHT="30">GX-E4</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="123" HEIGHT="30">2023년~2025년</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="80" HEIGHT="30">2,730</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="78" HEIGHT="30">6순위</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="79" HEIGHT="30">GX-H9</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="123" HEIGHT="30">2023년~2025년</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="80" HEIGHT="30">1,657</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="78" HEIGHT="30">7순위</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="79" HEIGHT="30">GX-I7</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="123" HEIGHT="30">2023년~2025년</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="80" HEIGHT="30">10,925</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="78" HEIGHT="30">5순위</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ROWSPAN="3" ALIGN="CENTER" WIDTH="122" HEIGHT="90">임상</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="79" HEIGHT="30">GX-188E</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="123" HEIGHT="30">2023년~2025년</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="80" HEIGHT="30">34,714</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="78" HEIGHT="30">1순위</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="79" HEIGHT="30">GX-E4</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="123" HEIGHT="30">2023년~2025년</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="80" HEIGHT="30">18,000</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="78" HEIGHT="30">2순위</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="79" HEIGHT="30">GX-I7</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="123" HEIGHT="30">2023년~2025년</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="80" HEIGHT="30">9,479</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="78" HEIGHT="30">3순위</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" COLSPAN="2" ALIGN="CENTER" WIDTH="201" HEIGHT="30">연구재료비</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="123" HEIGHT="30">2023년~2025년</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="80" HEIGHT="30">2,124</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="78" HEIGHT="30">8순위</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" COLSPAN="4" ALIGN="CENTER" WIDTH="413" HEIGHT="30">총합계</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="80" HEIGHT="30">85,217</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="78" HEIGHT="30" USERMARK=" B">-</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" WIDTH="572" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="563"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="572" HEIGHT="30">출처: 당사 제시</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN USERMARK="F-GL11">[주요용어] </SPAN>
</P>

<TABLE BORDER="1" WIDTH="1024" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="364"></COL>
<COL WIDTH="642"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="373" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P>구분</P>
</TD>

<TD WIDTH="651" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P>내용</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="373" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">PPQ: Process Performance Qualification</TD>
<TD WIDTH="651" VALIGN="MIDDLE" HEIGHT="30">공정성능적격성평가(공정을 3회 반복해서 동일한 결과물을 검증하는 과정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="373" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">E/L Study: Extractables and Leachables Study</TD>
<TD WIDTH="651" VALIGN="MIDDLE" HEIGHT="30">용출및첨출물실험 (공정과정의 불순물, 용기등에서 나올수 있는 불순물을 검증하는과정</TD>
</TR>
</TBODY>
</TABLE>
<P>상기 각 파이프라인별 자금사용 세부사항은 다음과 같습니다.</P>
<P>(1) GX-188EGX-188E(자궁경부암 치료백신, HPV16/18 유래암치료 DNA 백신)은 국내에서 진행성/재발성 자궁경부암 환자를 대상으로 임상2상을 진행하고 있으며, 현재 65 명의 환자를 대상으로 투약을 완료하여 올해 12월까지 최종보고서(CSR)을 작성할 예정에 있습니다. 신속처리대상지정 및 조건부허가 신청을 위한 절차를 식품의약품안전처(MFDS)와 논의하고 있으며, 이와 병행하여 다국가 임상3상을 위한 임상시험계획승인(IND) 신청을 논의하고 있습니다. 다국가 임상3상을 수행하기 위한 선제적 제반비용이 필요하며, EDC(전자데이터수집)시스템, CRO 인력구성 등 임상시험계획승인(IND) 신청 약 3~4개월 이전에 외부업체와의 계약금 및 비용이 소요됩니다. 또한, 현재 논의 중인 임상시험계획승인(IND)이 빠르게 승인되어 환자모집이 진행되면 초기 사용 비용은 증가할 수 있습니다. 이에 따라 향후 다국가 임상3상 개발비용 약 347억원과 CMC비용 56억원이 소요될 것으로 예상하고 있습니다.신속처리대상지정 및 조건부허가 제도는 대체치료제가 없는 중대한 질환, 희귀질환관리법에 따른 희귀질환, 대유행 감염병의 예방·치료를 목적으로 하는 첨단바이오의약품으로 지정된 의약품이 초기 임상시험 결과 또는 임상시험 과정에서 안전성·유효성이 확보됨을 확인할 수 있는 자료를 제시하는 경우 추후 임상시험(임상3상) 자료를 제출하는 것을 조건으로 허가하는 제도입니다. 이는 대체치료제가 없고 생명을 위헙하는 암 등 중대한 질환의 치료목적으로 하는 경우에 지정될 수 있으나, 대상질환 및 해당 질환에 대한 표준 치료법의 빠른 변화로 신청 당시 임상 현장 상황에 따라 달리 해석될 수 있으므로, 신속처리대상 지정신청이 신속처리대상지정을 받았다는 것을 의미하는 것은 아닙니다. 그러므로 신속처리대상 지정을 받지 못할 경우 조건부 허가 대상이 되지 못할 가능성이 있으며, 따라서 회사는 이와는 별도로 임상3상을 위한 준비를 병행하여 진행할 예정입니다. 임상 3상을 위한 준비 비용은 금번 유상증자를 통해 조달한 자금으로 충당할 예정입니다.당사가 계획중인 진행성/재발성 자궁경부암 환자를 대상으로 하는 다국가 임상3상 개발 계획 및 일정, 임상시험비용 세부내역 및 임상시험 개요는 아래와 같습니다.</P>

<P USERMARK=" 0X0000FF">
<SPAN USERMARK=" 0X000000">[GX-188E DNA 치료백신의 향후 개발 계획 및 일정]</SPAN>
</P>

<TABLE BORDER="1" WIDTH="776" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="91"></COL>
<COL WIDTH="91"></COL>
<COL WIDTH="63"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH ROWSPAN="2" WIDTH="100" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>분류</P>
</TH>

<TH ROWSPAN="2" WIDTH="100" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>세부</P>
</TH>

<TH WIDTH="72" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2022년</P>
</TH>

<TH COLSPAN="4" WIDTH="168" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2023년</P>
</TH>

<TH COLSPAN="4" WIDTH="168" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2024년</P>
</TH>

<TH COLSPAN="4" WIDTH="168" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2025년</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="72" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" WIDTH="100" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90">
<P>임상개발</P>
</TD>

<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">
<P>임상2상</P>
</TD>

<TD WIDTH="72" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">
<P>조건부허가</P>
</TD>

<TD WIDTH="72" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">
<P>임상3상</P>
</TD>

<TD WIDTH="72" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="100" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>전기천공기</P>
</TD>
<TD WIDTH="100" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">해외등록</TD>

<TD WIDTH="72" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>●</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P> </P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" WIDTH="761" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="752"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="761" HEIGHT="53">주) 상기 일정은 임상개발 전략의 변경, 규제기관의 정책변화, 시장 환경 변화에 따라 일부 또는 전체가 변경될 수 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="761" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P USERMARK=" B"></P>
<P>[진행성/재발성 자궁경부암 환자의 2차 치료제로서 다국가 임상3상 개요]</P>

<TABLE BORDER="1" WIDTH="1038" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="151"></COL>
<COL WIDTH="869"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="160" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>구분</P>
</TH>

<TH WIDTH="878" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>내용</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="160" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>임상시험</P>
<P>대상국가</P>
</TD>

<TD WIDTH="878" VALIGN="MIDDLE" HEIGHT="53">
<P>한국, 남미 및 동남아시아 (예상)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="160" ALIGN="CENTER" HEIGHT="53" VALIGN="MIDDLE">
<P> 임상시험의</P>
<P>목적</P>
</TD>

<TD WIDTH="878" HEIGHT="53" VALIGN="MIDDLE">
<P>임상시험의 주요 목표는 진행성 및/또는 재발성 자궁경부암 환자를 대상으로 대조군 대비 GX-188E과 펨브롤리주맙(또는 다른 면역관문억제제) 병용투여의 유효성 확증을 목적으로 한다.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="160" ALIGN="CENTER" HEIGHT="122" VALIGN="MIDDLE">
<P> 임상시험 수행방법</P>
</TD>

<TD WIDTH="878" HEIGHT="122" VALIGN="MIDDLE">
<P>시험 대상자 수: 약 400명</P>
<P>시험방법: 공개(Open), 무작위(Randomized), 활성대조군(Active-controlled), 다국가(Multi-national) 임상3상 디자인으로 대조군 대비 전체생존기간(Overall Survival)과 객관적 반응률 및 무진행생존기간(Progression Free Survival), 질병진행률(Disease Control Rate) 등을 평가하고자 한다.</P>
<P>임상연구기간: 약 4년(환자 모집 상황 및 투여 기간 등에 따라 일정은 변동될 수 있습니다.)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="160" ALIGN="CENTER" HEIGHT="122" VALIGN="MIDDLE">
<P>기대효과</P>
</TD>

<TD WIDTH="878" HEIGHT="122" VALIGN="MIDDLE">
<P>자궁경부암 발병의 주요 원인인 인유두종바이러스(HPV) 16형과 18형에서 생성되는 암 유발 단백질에 대한 면역반응을 유도하는 치료용 DNA 백신 후보물질로서 GX-188E는 Pembrolizumab과의 병용투여 시 기대할 수 있는 항암면역반응의 시너지가 임상적으로 확증되면, HPV로 인해 유발되는 자궁경부암뿐 아니라 두경부암 및 생식기암으로 다양한 적응증으로 확대할 수 있는 또 다른 시장 개척 가능성을 가지고 있다. 또한, 당사가 개발하고 있는 plasmid DNA 기반 항암 치료 백신으로서 다양한 암과 연계된 항원을 타겟으로 하는 항암 치료용 DNA 백신 개발을 위한 초석이 될 것으로 기대한다.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="160" ALIGN="CENTER" HEIGHT="76" VALIGN="MIDDLE">
<P> 임상비용 산정근거</P>
</TD>

<TD WIDTH="878" HEIGHT="76" VALIGN="MIDDLE">
<P>기 허가된 항암화학요법에서 전체생존기간의 중앙값 9개월 대비 GX-188E 병용용법의 생존기간의 중앙값 14개월을 기반으로 필요한 시험대상자 수를 산출하였으며(약 388명), 국내에서 수행된 임상1b/2상 사용된 환자 1인당 한화 약 9천만원을 기준으로 임상시험연구비 약 347억원이 산정되었습니다.</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" WIDTH="1039" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1030"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1039" HEIGHT="30">주) 상기 일정은 임상개발 전략의 변경, 규제기관의 정책변화, 시장 환경 변화에 따라 일부 또는 전체가 변경될 수 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1039" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P USERMARK=" B"></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="1035">

<COLGROUP>
<COL WIDTH="907"></COL>
<COL WIDTH="110"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-12" WIDTH="916" HEIGHT="31">[진행성/재발성 자궁경부암 환자의 2차 치료제로서 글로벌 임상3상 상세 임상 개발비용]</TD>
<TD WIDTH="119" HEIGHT="31" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="1034">

<COLGROUP>
<COL WIDTH="298"></COL>
<COL WIDTH="718"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-12" WIDTH="307" HEIGHT="31"></TD>
<TD WIDTH="727" HEIGHT="31" ALIGN="RIGHT" VALIGN="MIDDLE"> (단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="1034" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="134"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="62"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH ROWSPAN="2" WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>프로젝트</P>
</TH>

<TH ROWSPAN="2" WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>항목</P>
</TH>

<TH COLSPAN="4" WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2023년</P>
</TH>

<TH COLSPAN="4" WIDTH="248" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2024년</P>
</TH>

<TH COLSPAN="4" WIDTH="248" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2025년</P>
</TH>

<TH ROWSPAN="2" WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P> 총액</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="5" WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="150">
<P>임상3상</P>
<P>진행 및/또는 재발성 자궁경부암</P>
</TD>

<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>임상비용</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,784</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>2,676</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>2,800</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>4,200</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>4,200</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>2,800</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>2,700</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>4,050</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>4,050</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>2,700</P>
</TD>

<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>31,960</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>임상약 관리</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>85</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>56</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>85</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>127</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>85</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>127</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>127</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>85</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>85</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>127</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>127</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>85</P>
</TD>

<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,200</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>분석비용</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>20</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>30</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>44</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>66</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>39</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>59</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>89</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>133</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>70</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>105</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>158</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>237</P>
</TD>

<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,050</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>기타</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>25</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>37</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>55</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>83</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>25</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>37</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>55</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>83</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>13</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>19</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>29</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>43</P>
</TD>

<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>504</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="106" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>합계</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>129</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>123</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,968</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>2,953</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>2,949</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>4,423</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>4,471</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>3,101</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>2,868</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>4,301</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>4,364</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>3,065</P>
</TD>

<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>34,714</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="1039">

<COLGROUP>
<COL WIDTH="1030"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1039" HEIGHT="30">주) 상기 일정은 임상개발 전략의 변경, 규제기관의 정책변화, 시장 환경 변화에 따라 일부 또는 전체가 변경될 수 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1039" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P> </P>
<P>CMC 비용은 ㈜바이넥스(위탁생산 및 개발 서비스업, CDMO)를 통해 PPQ 배치 생산 및 분석 32억원, 안정성시험 12억원,  E/L Study 외 11.9억원으로, 총 55.9억원을 사용할 계획입니다. 각 비용에 대한 세부내역은 하기와 같으며, 해당 연구에 필요한 견적을 근거로 하여 비용을 추산하였습니다.</P>
<P USERMARK=" B"> </P>

<P USERMARK=" B">
<SPAN USERMARK=" !B">[GX-188E 관련 CMC 비용 세부 내역]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="872">

<COLGROUP>
<COL WIDTH="298"></COL>
<COL WIDTH="556"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-12" WIDTH="307" HEIGHT="31"></TD>
<TD WIDTH="565" HEIGHT="31" ALIGN="RIGHT" VALIGN="MIDDLE"> (단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="872" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="79"></COL>
<COL WIDTH="154"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="53"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH ROWSPAN="2" WIDTH="88" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>분류</P>
</TH>

<TH ROWSPAN="2" WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>세부</P>
</TH>

<TH COLSPAN="4" WIDTH="203" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2023년</P>
</TH>

<TH COLSPAN="4" WIDTH="178" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2024년</P>
</TH>

<TH COLSPAN="4" WIDTH="178" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2025년</P>
</TH>

<TH ROWSPAN="2" WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P> 총액</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="4" WIDTH="88" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="120">
<P>GX-188E</P>
</TD>

<TD WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>PPQ 생산 (DS,DP)</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>800</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>800</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>800</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>800</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>3,200</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>안정성 시험</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>400</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>400</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>400</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,200</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>E/L study 외</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>39</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>200</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>363</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>200</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>386</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,188</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>합계</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>800</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>800</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>800</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,239</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>200</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>763</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>200</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>786</P>
</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>5,588</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" WIDTH="872" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="863"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="872" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P USERMARK=" B"></P>
<P>(2) GX-I7</P>

<P USERMARK=" 0X0000FF">
<SPAN USERMARK=" 0X000000">불응성 또는 재발성 삼중음성유방암에 대한 GX-I7(면역항암제)의 임상2상에 대한 중간결과를 올해 6월 ASCO(미국임상종양학회)에서 발표한 바 있습니다. 향후 상업화를 위해 PPQ 배치 생산 및 분석에 대한 투자를 계획하고 있으며CMC 비용으로 약 127억원,임상비용으로 약 95억원을 사용할 계획입니다.</SPAN>
</P>
<P> </P>
<P>당사는 불응성 또는 재발성 삼중음성유방암 환자를 대상으로 임상1b/2상을 통해 PD-L1 양성(CPS≥10) 환자에서의 긍정적인 결과를 바탕으로 금번 유상증자 자금의 일부를 활용하여 불응성 또는 재발성 삼중음성유방암 환자를 대상으로 하는 다국가 임상2상을 계획하고 있습니다. 임상2상의 향후 개발 계획 및 일정, 임상시험비용 세부내역 및 임상시험 개요는 아래와 같습니다.</P>
<P>[GX-I7 면역항암제의 향후 개발 계획 및 일정]</P>

<TABLE BORDER="1" WIDTH="813" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="145"></COL>
<COL WIDTH="93"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="32"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="154" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2">
<P>분류</P>
</TH>

<TH WIDTH="102" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2">
<P>세부</P>
</TH>

<TH WIDTH="131" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" COLSPAN="4">
<P>2022년</P>
</TH>

<TH COLSPAN="4" WIDTH="140" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2023년</P>
</TH>

<TH COLSPAN="4" WIDTH="140" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2024년</P>
</TH>

<TH COLSPAN="4" WIDTH="146" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2025년</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="41" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="2" WIDTH="154" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="106">
<P>삼중음성 유방암</P>
</TD>

<TD WIDTH="102" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>임상1b/2상</P>
<P>(국내)</P>
</TD>
<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">●</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="41" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="102" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>임상2상</P>
<P>(다국가)</P>
</TD>
<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="41" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="2" WIDTH="154" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="106">
<P>재발성 교모세포종</P>
</TD>

<TD WIDTH="102" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>임상2상</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="41" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="102" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>임상2/3상</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="35" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="41" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> ●</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="815">

<COLGROUP>
<COL WIDTH="806"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="815" HEIGHT="53">주) 상기 일정은 임상개발 전략의 변경, 규제기관의 정책변화, 시장 환경 변화에 따라 일부 또는 전체가 변경될 수 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="815" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P USERMARK=" B"> </P>
<P>[불응성 또는 재발성 삼중음성유방암 다국가 임상 2상 상세 임상 개발 비용]</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="920">

<COLGROUP>
<COL WIDTH="298"></COL>
<COL WIDTH="604"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-12" WIDTH="307" HEIGHT="31"></TD>
<TD WIDTH="613" HEIGHT="31" ALIGN="RIGHT" VALIGN="MIDDLE"> (단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="922" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="204"></COL>
<COL WIDTH="89"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH ROWSPAN="2" WIDTH="213" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>프로젝트</P>
</TH>

<TH ROWSPAN="2" WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>항목</P>
</TH>

<TH COLSPAN="4" WIDTH="181" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2023년</P>
</TH>

<TH COLSPAN="4" WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2024년</P>
</TH>

<TH COLSPAN="4" WIDTH="181" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2025년</P>
</TH>

<TH ROWSPAN="2" WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P> 총액</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="5" WIDTH="213" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="150">
<P>임상2상</P>
<P>불응성 또는 재발성 삼중음성유방암</P>
</TD>

<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>임상비용</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,246</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>351</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>351</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>351</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,279</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>351</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>970</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>351</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>351</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>351</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>770</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,070</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>7,794</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>임상약 관리</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>185</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>41</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>41</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>41</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>41</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>41</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>185</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>41</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>41</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>185</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>41</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>41</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>926</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>분석비용</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>123</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>27</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>27</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>27</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>27</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>27</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>123</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>27</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>27</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>123</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>27</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>27</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>617</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>기타</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>28</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>9</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>9</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>9</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>9</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>9</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>9</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>9</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>9</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>9</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>9</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>28</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>142</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>합계</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,583</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>428</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>428</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>428</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,357</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>428</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,287</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>428</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>428</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>668</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>847</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,167</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>9,479</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="923">

<COLGROUP>
<COL WIDTH="914"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="923" HEIGHT="30">주) 상기 일정은 임상개발 전략의 변경, 규제기관의 정책변화, 시장 환경 변화에 따라 일부 또는 전체가 변경될 수 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="923" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P USERMARK=" B"> </P>

<TABLE ACLASS="NORMAL" WIDTH="600" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="591"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="600" HEIGHT="30">[삼중음성유방암 환자 대상 다국가 임상 2상 개요]</TD>
</TR>
</TBODY>
</TABLE>
<PGBRK></PGBRK>

<TABLE BORDER="1" WIDTH="925" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="149"></COL>
<COL WIDTH="758"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="158" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>구분</P>
</TH>

<TH WIDTH="767" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>내용</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>임상시험 대상국가</P>
</TD>

<TD WIDTH="767" VALIGN="MIDDLE" HEIGHT="30">
<P>한국, 중국 및 동남아시아 (예상)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>임상시험의 목적</P>
</TD>

<TD WIDTH="767" HEIGHT="53">
<P>임상시험의 주요 목표는 진행성 및/또는 재발성 삼중음성유방암 환자를 대상으로 대조군 대비 GX-I7과 펨브롤리주맙(또는 다른 면역관문억제제) 병용투여의 안전성과 유효성 확인을 목적으로 한다.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145">
<P>임상시험 수행방법</P>
</TD>

<TD WIDTH="767" HEIGHT="145">
<P>시험 대상자 수: 약 114명 </P>
<P>공개(Open), 무작위(Randomized), 활성대조군(Active-controlled), 다국가(Multi-national) 임상2/3상 디자인으로 대조군 대비 객관적 반응률(ORR) 및 무진행생존기간(Progression Free Survival), 전체생존기간(Overall Survival), 질병진행률(Disease Control Rate) 등을 평가하고자 한다.</P>
<P>임상연구기간: </P>
<P>약 4년(환자 모집 상황 및 투여 기간 등에 따라 일정은 변동될 수 있다.)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145">
<P>기대효과</P>
</TD>

<TD WIDTH="767" HEIGHT="145">
<P>단독 투여 시 림프구감소증을 개선시키는 효과와 더불어 암환자에서 종양 침윤림프구(TIL)의 수를 증가시키고, Pembrolizumab과 병용 투여 시 PD-1 차단을 유의하게 강화시켜 높은 항암 효과를 기대할 수 있습니다. 항암화학치료제와 비교하여 독성이 적은 장점도 있어 다양한 면역항암제와의 병용요법에서도 매우 안전하게 투여할 수 있습니다. 따라서 GX-I7은 다양한 면역항암제와의 병용요법으로 항암면역에 중요한 역할을 하는 림프구 수를 증가시켜 항암효과를 증가시키는 약제로서 최초의 신약이 될 것으로 기대합니다.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<P>임상비용 산정근거</P>
</TD>

<TD WIDTH="767" HEIGHT="76">
<P>기 허가된 항암화학요법에서 객관적반응율 약 11% 대비 GX-I7 및 Pembrolizumab 병용요법의 객관적반응율 40% 이상을 추정할 때, 필요한 시험대상자 수를 산출하였으며(약 114명), 국내에서 수행된 임상1b/2상 사용된 환자 1인당 한화 약 8.3천만원을 기준으로 임상시험연구비 약 95억원이 산정되었습니다.</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="926">

<COLGROUP>
<COL WIDTH="917"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="926" HEIGHT="30">주) 상기 내용은 임상개발 전략의 변경, 규제기관의 정책변화, 시장 환경 변화에 따라 일부 또는 전체가 변경될 수 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="926" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P USERMARK=" B"> </P>
<P>CMC 비용은 글로벌 CDMO (삼성바이오로직스 및 Patheon)을 이용한 PPQ 배치 생산 및 분석비용 69억원, E/ L study 40억원으로 총109.3억원이 사용할 계획입니다. 각 비용에 대한 세부내역은 하기와 같으며, 해당 연구에 필요한 견적을 근거로 하여 비용을 추산하였습니다.</P>
<P USERMARK=" 0XFF1200"> </P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="1006">

<COLGROUP>
<COL WIDTH="298"></COL>
<COL WIDTH="690"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-12" WIDTH="1006" HEIGHT="31" COLSPAN="2">[GX-I7 관련 CMC 비용 세부 내역]</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="307" HEIGHT="31" USERMARK="F-12"></TD>
<TD WIDTH="699" HEIGHT="31" ALIGN="RIGHT" VALIGN="MIDDLE"> (단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="1007" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="75"></COL>
<COL WIDTH="154"></COL>
<COL WIDTH="49"></COL>
<COL WIDTH="49"></COL>
<COL WIDTH="49"></COL>
<COL WIDTH="49"></COL>
<COL WIDTH="49"></COL>
<COL WIDTH="48"></COL>
<COL WIDTH="48"></COL>
<COL WIDTH="48"></COL>
<COL WIDTH="48"></COL>
<COL WIDTH="48"></COL>
<COL WIDTH="48"></COL>
<COL WIDTH="48"></COL>
<COL WIDTH="62"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH ROWSPAN="2" WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>프로젝트</P>
</TH>

<TH ROWSPAN="2" WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>항목</P>
</TH>

<TH COLSPAN="4" WIDTH="232" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2023년</P>
</TH>

<TH COLSPAN="4" WIDTH="229" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2024년</P>
</TH>

<TH COLSPAN="4" WIDTH="228" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2025년</P>
</TH>

<TH ROWSPAN="2" WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>총액</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90">
<P>GX-I7</P>
</TD>

<TD WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>PPQ 생산 (DS,DP)</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,300</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,300</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,300</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,000</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,000</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,000</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>6,900</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>E/L study 외</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>419</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,000</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,000</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,000</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>606</P>
</TD>

<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>4,025</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>합계</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,300</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,300</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,300</P>
</TD>

<TD WIDTH="58" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,000</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,419</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,000</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,000</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,000</P>
</TD>

<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>1,000</P>
</TD>
<TD WIDTH="57" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">606</TD>

<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>10,925</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" WIDTH="1008" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="999"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1008" HEIGHT="30">주) 상기 비용은 환율변동 등으로 일부 변경될 수 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1008" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P>(3) GX-H9</P>
<P>GX-H9은 한독과 공동 개발중인 지속형 성장호르몬 입니다. 중국 파트너사인 I-MAB 에서는 중국에서 임상3상을 진행하고 있으며, 당사와 한독은 중국 I-MAB과 협업하여 현재 다국가 임상3상시험을 준비중에 있습니다. 이에 향후 CMC 비용으로 약 39억원의 비용이 사용될 것으로 예상하고 있습니다.</P>
<P> </P>
<P>CMC 비용은 중국 파트너사인 아이맵(I-MAB)과의 협업으로 제형 및 공정개발 9.0억원, 디바이스 개발 13.6억원, 총 16.6억원이 사용할 계획입니다. 각 비용에 대한 세부내역은 하기와 같으며, 해당 연구에 필요한 견적을 근거로 하여 비용을 추정하였습니다.</P>
<P USERMARK=" 0XFF1200"> </P>

<TABLE ACLASS="NORMAL" WIDTH="840" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="831"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="840" HEIGHT="30">[GX-H9 관련 CMC 비용 세부 내역] </TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="840">

<COLGROUP>
<COL WIDTH="298"></COL>
<COL WIDTH="524"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-12 B" WIDTH="307" HEIGHT="31"></TD>
<TD WIDTH="533" HEIGHT="31" ALIGN="RIGHT" VALIGN="MIDDLE"> (단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="840" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="75"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="53"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH ROWSPAN="2" WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>프로젝트</P>
</TH>

<TH ROWSPAN="2" WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>항목</P>
</TH>

<TH COLSPAN="4" WIDTH="188" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2023년</P>
</TH>

<TH COLSPAN="4" WIDTH="178" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2024년</P>
</TH>

<TH COLSPAN="4" WIDTH="178" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2025년</P>
</TH>

<TH ROWSPAN="2" WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>총액</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90">
<P>GX-H9</P>
</TD>

<TD WIDTH="150" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">
<P>제형 및 공정 개발</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>300</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>300</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>300</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="62" ALIGN="CENTER" HEIGHT="30">
<P>900</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="150" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">
<P>디바이스 개발</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>357</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>
<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">200</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>
<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">200</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>
<TD WIDTH="62" ALIGN="CENTER" HEIGHT="30">757</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>합계</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>300</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>300</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>300</P>
</TD>

<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>357</P>
</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>
<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">200</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>
<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">200</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>
<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>

<TD WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>
<TD WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="62" ALIGN="CENTER" HEIGHT="30">1,657</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" WIDTH="840" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="831"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="840" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P>(4) GX-E4</P>
<P>당사에서 개발한 GX-E4(지속형 빈혈치료제)는 지속형 빈혈치료제로 합자회사인 인도네시아 KGBio와 함께 비투석 신장질환 환자를 대상으로 아세안, 호주, 한국을 포함한 다국가 임상3상을 진행하고 있으며, 2022년 7월 환자 모집이 완료되었습니다.이후, 약 1년 동안의 2주 또는 4주 간격으로 반복 투여하면서 장기 안전성과 유효성에 대해 추적관찰하고 있습니다. 유럽으로의 진출을 위해 당사가 계획한 투석 환자를 대상으로 하는 임상3상 계획을 유럽 규제기관(EMA)와의 사전상담(Scientific Advisory Meeting)을 준비하고 있으며, 2023년 임상3상을 착수할 계획입니다. 향후 투석 환자를 대상으로 한 다국가 임상3상을 위해 약 180억원과 CMC 비용으로 약 27.3억원을 사용할 계획입니다.</P>
<P></P>
<P>임상3상의 향후 개발 계획 및 일정, 임상시험비용 세부내역 및 임상시험 개요는 아래와 같습니다.</P>
<P> </P>

<TABLE ACLASS="NORMAL" WIDTH="667" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="658"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="667" HEIGHT="30">[GX-E4 향후 개발 계획 및 일정]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="668" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
<COL WIDTH="23"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ROWSPAN="2" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>분류</P>
</TH>

<TH WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ROWSPAN="2" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>세부</P>
</TH>

<TH WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" COLSPAN="4" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2022년</P>
</TH>

<TH COLSPAN="4" WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2023년</P>
</TH>

<TH COLSPAN="4" WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2024년</P>
</TH>

<TH COLSPAN="4" WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2025년</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3Q</TH>
<TH WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4Q</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="4" WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="212">
<P>임상개발</P>
</TD>

<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>임상3상</P>
<P>(비투석)</P>
</TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">●</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>국내허가</P>
<P>(비투석)</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>임상3상</P>
<P>(투석)</P>
</TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>국내허가</P>
<P>(투석)</P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>
<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"></TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> </P>
</TD>

<TD WIDTH="32" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>●</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="668">

<COLGROUP>
<COL WIDTH="659"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="668" HEIGHT="53">주) 상기 일정은 임상개발 전략의 변경, 규제기관의 정책변화, 시장 환경 변화에 따라 일부 또는 전체가 변경될 수 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="668" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P USERMARK=" 0X0000FF"> </P>

<TABLE ACLASS="NORMAL" WIDTH="666" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="657"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="666" HEIGHT="30">[투석 환자 대상 빈혈치료제로서 다국가 임상3상 개요]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="665" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="145"></COL>
<COL WIDTH="502"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="154" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>구분</P>
</TH>

<TH WIDTH="511" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>내용</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>임상시험 대상국가</P>
</TD>

<TD WIDTH="511" VALIGN="MIDDLE" HEIGHT="30">
<P>한국, 아세안, 호주 및 유럽을 포함한 약 15개 국가 (예상)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<P>임상시험의</P>
<P>목적</P>
</TD>

<TD WIDTH="511" HEIGHT="76">
<P>임상시험의 주요 목표는 투석을 받는 신장질환 환자를 대상으로 대조군 (네스프 또는 아라네스프) 대비 GX-E4의 유효성(헤모글로빈 수치 개선)을 확증하고 장기 안전성을 확인하기 위한 목적으로 한다.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="168">
<P>임상시험 수행방법</P>
</TD>

<TD WIDTH="511" HEIGHT="168">
<P>시험 대상자 수: 약 230명 </P>
<P>공개(Open), 무작위(Randomized), 활성대조군(Active-controlled), 다국가(Multi-national) 임상3상 디자인으로 대조군 대비 기저치 대비 헤모글로빈의 변화가 대조군과 비요하여 비열등한지를 평가하고자 한다.</P>
<P>임상연구기간: 약 3년(환자 모집 상황 및 투여 기간 등에 따라 일정은 변동될 수 있습니다.)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<P>기대효과</P>
</TD>

<TD WIDTH="511" HEIGHT="99">
<P>당사의 hyFc 기술 기반의 첫 번째 다국가 임상3 상 제품으로, 상용화된 경쟁 제품 대비 동등 수준 이상 의 효과뿐 아니라, 가격 경쟁력을 갖추고 있어 상업화 이후 빠르게 시장 점유율을 높일 것으로 기대합니다.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<P>임상비용 산정근거</P>
</TD>

<TD WIDTH="511" HEIGHT="99">
<P>비투석 환자를 대상으로 진행한 임상3상에서의 비용을 근거로 1인당 약 8천만원을 추정였고, 임상시험대행업체(CRO)인 OPIS로부터 수령한 임상시험 견적서를 근거로 임상시험 연구비 약 180억원이 산정되었습니다.</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="666">

<COLGROUP>
<COL WIDTH="657"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="666" HEIGHT="53">주) 상기 일정은 임상개발 전략의 변경, 규제기관의 정책변화, 시장 환경 변화에 따라 일부 또는 전체가 변경될 수 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="666" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P USERMARK=" 0X0000FF B"> </P>

<TABLE ACLASS="NORMAL" WIDTH="901" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="892"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="901" HEIGHT="30">[다국가 임상3상 상세 임상 개발 비용]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="899">

<COLGROUP>
<COL WIDTH="298"></COL>
<COL WIDTH="583"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-12" WIDTH="307" HEIGHT="31"></TD>
<TD WIDTH="592" HEIGHT="31" ALIGN="RIGHT" VALIGN="MIDDLE"> (단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="899" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="69"></COL>
<COL WIDTH="89"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="54"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH ROWSPAN="2" WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>프로젝트</P>
</TH>

<TH ROWSPAN="2" WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>항목</P>
</TH>

<TH COLSPAN="4" WIDTH="220" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2023년</P>
</TH>

<TH COLSPAN="4" WIDTH="220" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2024년</P>
</TH>

<TH COLSPAN="4" WIDTH="220" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2025년</P>
</TH>

<TH ROWSPAN="2" WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P> 총액</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="5" WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="150">
<P>임상3상</P>
<P>투석중인</P>
<P>신장질환</P>
<P>환자</P>
</TD>

<TD WIDTH="98" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">
<P>임상비용</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>719</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,078</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,078</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>719</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>698</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,047</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,047</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>698</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>738</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,107</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,107</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>738</P>
</TD>

<TD WIDTH="63" ALIGN="RIGHT" HEIGHT="30">
<P>10,774</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="98" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">
<P>임상약 관리</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>353</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>529</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>529</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>353</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>200</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>300</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>300</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>200</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>200</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>300</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>300</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>200</P>
</TD>

<TD WIDTH="63" ALIGN="RIGHT" HEIGHT="30">
<P>3,764</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="98" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">
<P>분석비용</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>170</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>170</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>170</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>170</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="63" ALIGN="RIGHT" HEIGHT="30">
<P>1,681</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="98" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">
<P>기타</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>195</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>195</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>195</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>195</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>125</P>
</TD>

<TD WIDTH="63" ALIGN="RIGHT" HEIGHT="30">
<P>1,781</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>합계</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,437</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,973</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,973</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,437</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,148</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,597</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,597</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,148</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,188</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,657</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,657</P>
</TD>

<TD WIDTH="55" ALIGN="CENTER" HEIGHT="30">
<P>1,188</P>
</TD>

<TD WIDTH="63" ALIGN="RIGHT" HEIGHT="30">
<P>18,000</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="904">

<COLGROUP>
<COL WIDTH="895"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="904" HEIGHT="30">주) 상기 일정은 임상개발 전략의 변경, 규제기관의 정책변화, 시장 환경 변화에 따라 일부 또는 전체가 변경될 수 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="904" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P USERMARK=" 0X0000FF B"> </P>
<P>CMC 비용은 KGM (KALBE GLOBAL MEDIKA)과의 협업으로 공정개발 5억원, 시료 생산 28.3억원으로, 총 27.3억원을 사용할 계획입니다. 각 비용에 대한 세부내역은 하기와 같으며, 인도네시아 합자 회사인 KGBio와 협업하여 진행할 계획입니다.</P>

<TABLE ACLASS="NORMAL" WIDTH="886" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="877"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="886" HEIGHT="30">[GX-E4 관련 CMC 비용 세부 내역]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="886">

<COLGROUP>
<COL WIDTH="298"></COL>
<COL WIDTH="570"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-12" WIDTH="307" HEIGHT="31"></TD>
<TD WIDTH="579" HEIGHT="31" ALIGN="RIGHT" VALIGN="MIDDLE"> (단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="887" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="75"></COL>
<COL WIDTH="173"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="38"></COL>
<COL WIDTH="33"></COL>
<COL WIDTH="53"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH ROWSPAN="2" WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>프로젝트</P>
</TH>

<TH ROWSPAN="2" WIDTH="182" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>항목</P>
</TH>

<TH COLSPAN="4" WIDTH="188" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2023년</P>
</TH>

<TH COLSPAN="4" WIDTH="193" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2024년</P>
</TH>

<TH COLSPAN="4" WIDTH="178" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2025년</P>
</TH>

<TH ROWSPAN="2" WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P> </P>
<P>총액</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>1Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>2Q</P>
</TH>

<TH WIDTH="47" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>3Q</P>
</TH>

<TH WIDTH="42" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>4Q</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90">
<P>GX-E4</P>
</TD>

<TD WIDTH="182" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">
<P>공정개발</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>250</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>250</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="62" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="62" ALIGN="CENTER" HEIGHT="30">
<P>500</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="182" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">
<P>시료 생산</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="62" ALIGN="CENTER" HEIGHT="30">
<P>1,016</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>907</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>307</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>
<TD WIDTH="62" ALIGN="CENTER" HEIGHT="30">2,230</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="182" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>합계</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>250</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>250</P>
</TD>
<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">-</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="62" ALIGN="CENTER" HEIGHT="30">
<P>1,016</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>907</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>

<TD WIDTH="47" ALIGN="CENTER" HEIGHT="30">
<P>307</P>
</TD>

<TD WIDTH="42" ALIGN="CENTER" HEIGHT="30">
<P>-</P>
</TD>
<TD WIDTH="62" ALIGN="CENTER" HEIGHT="30">2,730</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="887">

<COLGROUP>
<COL WIDTH="878"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="887" HEIGHT="53">주) 상기 일정은 임상개발 전략의 변경, 규제기관의 정책변화, 시장 환경 변화에 따라 일부 또는 전체가 변경될 수 있습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="887" HEIGHT="30">출처: 당사 제공</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P>2) 자금의 운용계획당사가 금번 유상증자를 통해 조달한 자금 중 일부 자금은 조달시기와 사용시기가 다소 차이가 있을 수 있습니다. 이에 조달로부터 사용시까지 미사용 자금에 대해서는 자금 사용시점 및 금리에 따라 적격금융기관의 수시입출금 예금, 정기예금 등 금융상품 또는 AA등급대(A1등급대)이상의 단기금융상품으로 운용할 예정입니다.</P>
<P></P>
</SECTION-3>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-7-0">Ⅶ. 신주인수권증서 발행내역</TITLE>
<P></P>

<LIBRARY>
<TABLE-GROUP ACLASS="SUBR_PUB" ADELETETABLE="N">
<TITLE ATOC="N">신주인수권증서 발행내역</TITLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="299"></COL>
<COL WIDTH="283"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="308" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="292" HEIGHT="30" AUNIT="STOCK" AUNITVALUE="1">(단위 : 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="599" BORDER="1">

<COLGROUP>
<COL WIDTH="54"></COL>
<COL WIDTH="128"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="134"></COL>
<COL WIDTH="124"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">청구일</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="137" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">발행시기</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="123" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">청구자</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="143" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">발행회사와의 관계</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="133" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">주식수</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" AUNIT="DMND_DT" AUNITVALUE="-">-</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="137" HEIGHT="30" ACODE="PUB_PRD">2022년 11월 22일</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="123" HEIGHT="30" ACODE="DMNDER">한국예탁결제원</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="143" HEIGHT="30" ACODE="RLT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="133" HEIGHT="30" ACODE="ST_CNT">5,750,084</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="466" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="133" HEIGHT="30" ACODE="ST_TOT">5,750,084</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>주) 총 모집주식수 5,797,102주(단수주 47,018주)</P>
<P></P>

<TABLE-GROUP ACLASS="SUBR_SUB" ADELETETABLE="N">
<TITLE ATOC="N">신주인수권증서에 의한 청약내역</TITLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="299"></COL>
<COL WIDTH="283"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="308" HEIGHT="30"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="292" HEIGHT="30" AUNIT="STOCK" AUNITVALUE="1">(단위 : 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="128"></COL>
<COL WIDTH="174"></COL>
<COL WIDTH="136"></COL>
<COL WIDTH="126"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="137" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">청약일</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="183" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">청약자</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">발행회사와의 관계</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="135" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">주식수</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="137" HEIGHT="53" AUNIT="SUB_DT" AUNITVALUE="20230103">2023년 01월 03일</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="183" HEIGHT="53" ACODE="SBER">한국예탁결제원(신주인수권증서 청약)</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="53" ACODE="RLT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="135" HEIGHT="53" ACODE="ST_CNT">4,972,068</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="137" HEIGHT="53" AUNIT="SUB_DT" AUNITVALUE="20230103">2023년 01월 03일</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="183" HEIGHT="53" ACODE="SBER">한국예탁결제원(초과청약)</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="53" ACODE="RLT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="135" HEIGHT="53" ACODE="ST_CNT">609,205</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="465" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="135" HEIGHT="30" ACODE="ST_TOT">5,581,273</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
</LIBRARY>

<P></P>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="L-0-0-8-0">Ⅷ. 실권주 처리내역</TITLE>
<P></P>
<P>1. 신주인수권증서 청약 실권주 및 단수주</P>

<TABLE WIDTH="605" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="596"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="605" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(단위 : 주)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="604" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="191"></COL>
<COL WIDTH="194"></COL>
<COL WIDTH="192"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="200" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P>신주인수권증서 청약 실권주</P>
</TH>

<TH WIDTH="203" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P>구주주 배정 단수주</P>
</TH>

<TH WIDTH="201" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P>실권주 및 단수주 총계</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">778,016</TD>
<TD WIDTH="203" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">47,018</TD>
<TD WIDTH="201" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">825,034</TD>
</TR>
</TBODY>
</TABLE>
<P>2. 신주인수권증서 청약 실권주 및 단수주 처리 내역 : 초과청약 배정</P>

<TABLE WIDTH="590" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="581"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="590" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(단위 : 주)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="590" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="149"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="267"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="158" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53">
<P>신주인수권증서 청약실권주 및 단수주</P>
</TH>

<TH WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53">
<P>초과청약주식수</P>
</TH>

<TH WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53">
<P>초과청약배정비율</P>
</TH>

<TH WIDTH="276" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53">
<P>비고</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">825,034</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">609,205</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">100%</TD>
<TD WIDTH="276" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">초과청약 배정 후 실권주 215,829주는일반공모 청약 진행</TD>
</TR>
</TBODY>
</TABLE>
<P>3. 초과청약 배정 후 실권주 및 단수주 처리 내역(실권주 일반공모)</P>

<TABLE WIDTH="604" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="595"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="604" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(단위: 주)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="604" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="193"></COL>
<COL WIDTH="243"></COL>
<COL WIDTH="141"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="202" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">실권주 일반공모 주식수</TH>
<TH WIDTH="252" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">실권주 일반공모 청약주식수</TH>
<TH WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">청약 경쟁률</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="202" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">215,829</TD>
<TD WIDTH="252" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">60,179,565</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">278.83</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
</SECTION-2>
</LIBRARY>

</SECTION-1>
</BODY>
</DOCUMENT>